Trial Profile
Epacadostat With Idarubicin and Cytarabine (EIC) for First-line Treatment of AML Patients Fit for Intensive Chemotherapy; a Phase I Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Epacadostat (Primary) ; Idarubicin (Primary) ; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Acronyms EIC-trial
- 07 Sep 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as IMP will not be further developed
- 26 Feb 2018 New trial record